Technology | Stents Drug Eluting | May 25, 2018

Abbott's Xience Sierra Stent Receives FDA Approval

New features on next-generation drug-eluting stent help doctors treat more difficult-to-reach blockages in patients' arteries

Abbott's Xience Sierra Stent Receives FDA Approval

May 25, 2018 — Abbott announced it received approval from the U.S. Food and Drug Administration (FDA) for Xience Sierra, the newest generation of the company's Xience everolimus-eluting coronary stent system. Design and technology advances in this generation of the device include features specifically designed for the treatment of complex blockages that now account for up to 70 percent of cases.1

Design innovations in Xience Sierra include a thinner profile, increased flexibility, longer lengths and small diameters. The new stent and delivery system were specifically developed for the treatment of complex cases, including people with multiple or totally blocked vessels.

More than 8 million people worldwide have received a Xience stent since its initial regulatory approvals in the EU in 2006 and in the U.S. in 2008. Its safety is supported in over 100 clinical trials and by 10 years of global real-world experience.

Abbott received regulatory approval for Xience Sierra in Japan in April 2018, and CE Mark in Europe in October 2017.

For more information: www.xiencestent.com

References

[1] 10,000,000 implants number is based on data of DES implants through Q1 2017. Comparative claim based on unit usage in U.S., Japan, China, India, top 5 Western Europe, and Korea. Other leading DES: BSX stents (Promus Element, Promus Element Plus, Promus Premier, Synergy); MDT stents (Resolute, Resolute Integrity, Resolute Onyx); Terumo stents (Nobori, Ultimaster); Biotronik stent (Orsiro); and Biosensors stent (BioMatrix). Data on file at Abbott Vascular.


Additional Content

News | Cath Lab

Nov. 2, 2026 — Royal Philips has announced U.S. commercial availability of the HyperVue Integrated System1, a new single ...

Home November 03, 2026
Home
News | Cath Lab

Aug. 28, 2026 — Heartflow, Inc. has announced late-breaking one-year results from an independent randomized clinical ...

Home August 28, 2026
Home
News | Cath Lab

July 9, 2026 — On July 9, Stereotaxis announced that it has completed its previously announced acquisition of Robocath ...

Home July 10, 2026
Home
News | Cath Lab

June 18, 2026 — Allegheny Health Network's (AHN) Allegheny General Hospital (AGH) has completed a $19 million renovation ...

Home June 18, 2026
Home
News | Cath Lab

May 28, 2026 — RWJBarnabas Health has earned Cardiac Catheterization Lab Accreditation from the American College of ...

Home May 29, 2026
Home
Subscribe Now